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ABSTRACT
Breast cancer is the most common malignancy in women globally, in which triple-negative breast cancer (TNBC) is more aggressive with poor 
prognosis and very less response to targeted hormone based treatment. It is a major cause of deaths among the women with breast cancer because of 
very few treatment options. The biomarkers could be a product of cancerous cell or molecule generated in response to cancer. It is used to understand 
the mechanism, prognosis, diagnosis as well as target for design and discovery of new drugs. The purpose of the study is to give a brief review on 
markers of TNBC.
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INTRODUCTION
Breast cancer is one of the most common malignant tumors among 
women, and it is a heterogeneous type of disease because of 
their therapy response. We can define its molecular subtypes by 
immunohistochemistry (IHC). Triple-negative breast cancer (TNBC) is 
one of the molecular subtypes of breast carcinoma represents by the lack 
of expression of estrogen receptor (ER), progesterone receptor (PR), 
and human epidermal growth factor receptor (HER 2). TNBC accounts 
for about 12.5-15% of all breast cancers [1]. TN breast carcinoma is 
more frequent in younger age (<50 years) with more aggressiveness 
and poorer prognosis. These are more prevalent in the African-
American population [2]. They need typical and differential molecular 
profile and distinct patterns of metastasis [3]. They metastasize 
commonly with lungs, central nervous system, and liver. TNBC varies 
16-42% in BRCA mutation [4,5]. TNBC can be further defined by two 
groups, i.e.,, basal-like (BL) and non-BL. Although all BL tumors are 
not triple negative [6]. However, in TN disease, all intrinsic molecular 
subtypes can be identified and majority tends to BL subtype (86%, 
depending from the various other studies done by Researchers) [7]. 
Initially, on the basis of hierarchical clustering, identified four intrinsic 
subtypes of breast cancers (BL, HER 2 enriched, luminal, and normal 
breast-like), which exhibits gene expression patterns. Subsequently, 
luminal breast cancer leads to sub- stratified into luminal A and 
luminal B, which expressed significantly in the classification system 
for prognosis [8-10]. For TNBC, there is no standard chemotherapy 
till date. BL-TNBC accounts up to approximately 25-80% of all TNBC 
patients [11]. The above data have been taken by IHC profiling for 
epidermal growth factor receptor (EGFR), CK 5/6 +, ER-, HER 2 -. BL-
TNBC can be further separated into two subgroups, BL1 and BL2 [12]. 
BL- TNBC exhibits the highest pathologic complete response (pCR) rates 
following chemotherapy [13]. However, various trials are going on and 
have been conducted in unselected patient’s populations. This review 
explores the biological features and biomarker expression profile of 
TNBC. In this article, we focused to understand and classified the TNBC 
based on similar gene expression, biological functions, and their clinical 
outcomes. The purpose of this study is to revise the specific therapeutic 
strategies, on the basis of gene profile having different for each specific 
TNBC subtypes. Hence, anti-EGFR, anti-vascular endothelial growth 
factor (VEGF), anti-p53, and anti-ki67, the prognostic biomarkers may 
provide a potential treatment option for TNBC.
Selection criteria and search
We conducted a PubMed, Medline search till July 2016, using the term 
“TNBC,” “Gene expression profiling,” “EGFR,” “VEGF,” “ki67,” “p53,” and 
“breast cancer” followed by “AND/OR” without any date restriction 
(Table 1). Publications written in other than the English language 
were excluded. We cross-referred the information obtained to identify 
clinically effective TNBC groupings with similar gene expression, 
biological functions, and clinical outcomes.
EGFR
Human EGFR (also known as HER 1/Erb 1) and its relative three other 
genes human EGFR 2, 3, and 4 (HER 2/Erb 2, also known as the neu 
oncogene, HER 3/Erb 3, and HER4/Erb 4) plays a major role in the 
control of cell growth and proliferation [14,15]. The defect in these 
receptors like genetic abnormalities leads to major defects in cancer 
cells [16]. Truly EGFR is the first epidermal receptor which recognizes 
as an oncogene [17,18]. EGFR is a 1,70,000 membranes bound tyrosine 
kinase. The protein product of EGFR plays a very major role in cell 
proliferation, protection against apoptosis and migration in activation 
of intracellular mediated pathways [19]. EGFR family inhibitors lead to 
two major classes: Monoclonal antibody that targets the extracellular 
module of this receptor: And other is small molecules that target the 
intracellular tyrosine kinase domain. Some FDA approved antibodies, 
cetuximab, and panitumumab target EGFR, while pertuzumab and 
trastuzumab target HER 2 [20].
EGFR highly overexpressed in majority of BL TN tumors [21]. BL 
TN tumors have seeking attention due to recognition as a distinct 
entity and due to poor prognosis that the diagnosis indicates. Some 
of the studies demonstrated TN tumors have a good response to an 
adjuvant anthracycline- based chemotherapy [22]. However, various 
clinical trials are still going on to target the possible therapeutics 
for TN tumors. Targeted anti-EGFR antibodies (e.g., cetuximab) 
and EGFR tyrosine kinase inhibitors (e.g., gefitinib) can provide a 
possible therapy modality [23,24]. As the outcome, the combination 
of cetuximab and gefitinib, give more promising result while did not 
showed the appropriate response by independent agent as compared 
to a study done [25]. In a cohort of unselected patients, EGFR-TKIs given 
as monotherapy did not provide any clinical benefit. A study showed 
the contradictory result, as indicates the inactivation of EGFR pathway 
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i6.17727
Review Article
25
Asian J Pharm Clin Res, Vol 10, Issue 6, 2017, 24-28
 Gupta et al. 
in TNBC by giving EGFR inhibitors [26]. Some authors demonstrated 
that one-third of BL TNBC develops distance metastasis in which 
EGFR markers were helpful in diagnosis of high risk of metastatic 
disease [27]. A study reported that IHC EGFR positive patients were 
significantly more likely to develop distance metastasis, which depicts 
EGFR as an important prognostic marker for distance metastasis. 
Whereas, in EGFR expression, there is no significant difference between 
TN tumors with metastasis and those without metastasis. A study 
showed a high frequency of EGFR expression, i.e., 91.3% in BL subtype 
of TN breast cancer, which suggests that this marker may be helpful 
to detect metastatic BL TN breast tumors and may be beneficial to the 
patients for treatment with anti-EGFR drugs [27]. Expressions of EGFR 
in TNBC from various studies has been shown in Table 2.
Ki67
Ki67 is nuclear non-histone protein and was named after its 
Researcher’s location, as, Ki stands for the University of Kiel, Germany, 
and 67 refers to the number of the clone on the 96-well plate. Ki67 
gene is known for its proliferating characteristics, as it is marker of 
proliferation. The expression of ki67 at peak in the phase of G1, S and 
G2 phase of cell cycle and absent in G0 phase [28]. Ki67 may predict 
as pathological exemption rate in breast cancer patient who followed 
neoadjuvant chemotherapy, whereas increased level of ki67 following 
neoadjuvant chemotherapy indicates a poor prognosis [29]. Hence, ki67 
has been considered to be one of the most relevant marker indicators in 
detecting the proliferation of the tumor cells [30]. According to a study, 
ki67 significantly expressed more in TNBC group when compared non-
TNBC patients [31]. The expression of ki67 in TNBC is higher than that 
of high-grade non-TNBC, which indicates that ki67 may play a role in 
prognosis of TNBC [32]. A study conducted in 2011, explained that 
TNBC with the higher expression of ki67 was associated with more 
aggressive clinicopathological features despite a higher pCR rate [33]. 
Some research articles suggest that the expression level of ki67 is 
presently considered to have significant prognostic and predictive 
values [34,35].
Ki67 expressed significantly in a higher stage of TN tumors and high 
lymph node metastasis [36]. They also suggested that the patients 
having higher expression of ki67 showed a significantly worse overall 
survival (OS) time. Hence, E-cadherin and ki67 when combined might 
be useful prognostic markers for adjuvant chemotherapy in Stage II 
TNBC patients. The debate on prognosis of ki67 in TNBC is still open, 
although various studies have established a relation between ki67 
and overall and disease-free survival. In a study, it is also suggested 
that the assessment of the main prognostic and predictive parameters 
such as ER, PgR, and HER 2 including along with ki67 should offer to 
the patients and their physicians a strong background on which the 
final therapeutic decision can be safely taken [37]. Ki67 leads to most 
promising yet controversial biomarker in breast cancer, which is 
implementing routinely in some of the pathology department but not 
all. Ki67 can be controversial but clinically implemented biomarker 
along with well-established biomarkers of ER, PR, and HER 2 are 
currently marketed gene expression signature [38]. In several meta-
analyses, it has been shown that ki67 as a prognostic marker as well 
as predictive marker (in neoadjuvant therapeutics). The “optimal” cut 
point of expression of ki67 has been still is under a big discussion topic 
which leads to matter that ki67 is a continuous marker, expressing the 
severe variation of the proliferative rates in different cancers. Due to 
this variation from several research and clinical trials, it is depicted 
that level of ki67 is quite difficult to standardize. However although, 
ki67 may be clinically interpreted directly by dividing its expression 
into two groups, i.e., tumors with a very low or very high expression of 
this marker. Instead of this limitation, the assessment of proliferation 
for cancer cell characterization ki67 plays an important pathological 
role [39].
VEGF
To support tumor growth, there is a requirement of increase formation 
of blood vessels. Tumor angiogenesis is a multistep process requiring 
signaling between tumor cells and several other cell types within the 
internal environment of tumor cells. Due to this process, they activate 
Table 1: PubMed literature search






Triple negative breast cancer OR basal-like breast cancer AND
IHC OR IHC AND
Biomolecular markers OR molecular subtype OR ER –ve AND PR –ve AND 
HER 2 neu –ve
Humans only













TNBC (n) EGFR 
expression (%)
Reference
TNBC: Triple-negative breast cancer
Table 3: VEGF expression in TNBC
Total 
number





TNBC: Triple-negative breast cancer, VEGF: Vascular endothelial growth factor, 
VEGFR: Vascular endothelial growth factor receptor
- 653 30 Teng et al. 2011
200 198 91 Yue et al. 2015
7048 767 30 Thike et al. 2010
683 136 7.4 Patil et al. 2011
- 21 BLBC 57 Nielsen et al. 2007
1726 282 37 Rakha et al. 2007
1132 103 23.3 Mehdizadeh et al. 2102
564 48 41 Ryden et al. 2010
Linderholm et al. 2008
96 43 90.5 Abeer Bahhnassy et al. 2015
1132 103 93.2 Mehdizadeh et al. 2012
- 73 77 Iosifidou et al. 2009
70 27 54 Chanana et al. 2012
69 35 34 Andre et al. 2009
679 87 Higher 
26
Asian J Pharm Clin Res, Vol 10, Issue 6, 2017, 24-28
 Gupta et al. 
overexpression of pro-angiogenic factors by the tumor cells, such as 
VEGF, referred to as the “angiogenic switch” [40]. VEGFs when binds 
to one receptor, it stimulates dimerization of receptor and initiates 
signal pathway which promotes growth and migration [41]. The 
tumor vascular growth can be inhibited by antiangiogenic therapy by 
interfering with the intracellular signaling of VEGF and VEGF receptor 
(VEGFR) [42-44]. A monoclonal humanized antibody was designed 
named as Bevacizumab and Ramucirumab to inhibit the interaction 
between VEGF ligands and receptors [45,46]. Expression of VEGF 
is controlled by many stimuli such as hypoxia, nitric oxide, HER 2, 
Tumor suppressor genes, growth factor, and oncogenes [47]. VEGF 
regulates neovascularization in tumors, by increasing the level of anti-
apoptotic proteins such as Bcl2, survivin, and XIAP. The endothelial 
cells undergo apoptosis, and newly formed vessels disintegrate due to 
its absence [48,49].
Now when it comes to TNBC, some researchers suggest that VEGF is 
one of the promising prognostic molecular markers. The expression of 
VEGF is elevated in DCIS and invasive breast cancer, and it is utilized for 
prognosis in breast carcinoma. The quantification of VEGF by IHC or 
immunoassay has shown a significant correlation with density. Higher 
expression of vascular density in breast tumors has been correlated 
with more aggressive tumor behavior and poor survival. Hence, 
microvessel density is now considered as one of the important factors 
which effects survival [50]. In a study conducted in 2009, was concluded 
that higher VEGF expressions are associated with shorter disease-free 
survival (DFS), OS, and DFS in TNBC [51]. It also stated that there was a 
direct correlation between serum and tissue level of VEGF to Grade III 
tumors, larger tumor size, positive lymph node, and poor survival with 
a decrease in level with chemotherapy. Expressions of VEGF in TNBC 
from various studies has been shown in Table 3
P53
P53 is a tumor suppressor gene which is encoded by the TP53 gene. 
P53 plays an important role as it regulates cell growth, proliferation, 
multiplication and apoptosis, and promotes stability of chromosomes. 
Any disruption of this function due to a mutation in p53 gene is done due 
to cellular stress by many pathways which are dependent on upstream 
regulatory kinase. 18-25% of primary breast carcinoma showed p53 
mutation [52]. According to a study, expression of p53 is significantly 
higher in TNBC comparatively than non-TNBC, which indicates in worse 
prognosis of TNBC [32]. Due to higher expression of p53 in TN tumors, 
it may be used as predictors for response to chemotherapeutic agents. 
The majority of breast tumors with the p53 mutation was ER negative 
and associated with decreased DFS [53]. Although the exact mechanism, 
which may involve in this association is still unclear.
In several studies, it is denoted that p53 is more favorable to response 
to NAC in patients with TNBC. For instance, p53 overexpression was 
strongly correlated with pCR rate in TNBCs [54]. The level of p53 
expression in TNBC with nodal metastasis was significantly higher than 
non-TNBC with same metastasis [55]. Heterogeneous p53 mutations, 
few of proteins may not be able to produce stability, which is detectible 
by IHC. The positive IHC results of p53 may be due to binding with other 
cellular proteins which gives accumulation of p53 expression.
Studies conducted by various researchers suggest that activation of p53 
gene is associated with aggressiveness of breast tumor and in TNBC 
patients; it significantly decreases the rate of DFS and OS [21,56-58]. It 
can be used for segregation of subclass, i.e., BL from core TNBC along 
with EGFR and cytokeratin [59]. In TNBC patients, p53 mutations are 
associated with poor response to chemotherapy [60]. Study conducted 
2016, demonstrated that elevated p53 expression in TNBC patients, 
presented the worst prognosis [61]. Measurement of p53 expression 
may assist in making treatment decisions and in predicting response 
to treatment, when apply before starting neoadjuvant chemotherapy, 
as when p53 combines with ki67, gives great predictive accuracy[62]. 
The frequency of p53 mutations was found to be higher in basal breast 
cancer as compared to Luminal type tumors [63]. Expressions of p53 in 
TNBC from various studies has been shown in Table 4.
CONCLUSION
TNBC is a cause of significant breast cancer mortality because of very 
few treatment options. Biomarkers can be useful as prognostic or 
predictive indicators which also suggest possible targeted therapies. 
TNBC are associated with a significantly higher expression of VEGF, 
EGFR, ki67, and p53 as compared with non-TNBC, which indicates 
the poorer prognosis in TN tumors. The emphasis should be put on 
research for targeted therapies of TNBC. New therapeutics alternatives 
should be investigated for patients with this subtype of breast cancer.
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